Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of Giredestrant, Triptorelin, and Anastrozole in Premenopausal Women with ER-Positive/HER2-Negative Early Breast Cancer

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying treatments for ER-positive/HER2-negative early breast cancer in premenopausal women. The study will explore the effects of different hormone therapies, including Giredestrant (also known by its code name RO7197597), Triptorelin, and Anastrozole. These medications are used to manage hormone levels and slow the growth of cancer cells. Giredestrant is a type of medication known as a selective estrogen receptor degrader (SERD), which helps to block the effects of estrogen on cancer cells. Triptorelin is a gonadotropin-releasing hormone (GnRH) agonist that reduces the production of certain hormones, and Anastrozole is an aromatase inhibitor that lowers estrogen levels in the body.

The purpose of this study is to determine if a combination of Giredestrant and Triptorelin is more effective in reducing cancer cell growth compared to a combination of Anastrozole and Triptorelin. Additionally, the study will assess if Giredestrant alone can provide similar benefits as when it is combined with Triptorelin. Participants will receive these treatments over a period of four weeks. The study will involve taking medication either orally or through an injection, depending on the specific treatment being tested.

Throughout the study, participants will undergo regular monitoring to assess the effects of the treatments on their cancer. This will include taking samples from the tumor before and after the treatment period to evaluate changes in cancer cell activity. The study aims to provide valuable insights into the effectiveness of these hormone therapies in managing ER-positive/HER2-negative early breast cancer in premenopausal women.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on specific criteria, including age, premenopausal status, and breast cancer characteristics.

    A pregnancy test is conducted before starting the treatment to ensure safety.

  2. Step 2

    Initial biopsy

    A biopsy of the tumor is performed to collect a sample for analysis. This helps in assessing the tumor's characteristics before treatment.

  3. Step 3

    Treatment phase

    The treatment involves taking medications for a period of 4 weeks.

    One group receives giredestrant in capsule form, taken orally, possibly combined with triptorelin, which is administered as an injection into the muscle.

    Another group receives anastrozole in tablet form, taken orally, along with triptorelin injections.

  4. Step 4

    Post-treatment biopsy

    After completing the treatment, a second biopsy is conducted to evaluate changes in the tumor.

  5. Step 5

    Analysis and follow-up

    The primary focus is on the change in the Ki-67 index, which measures cell growth activity, between the initial and post-treatment biopsies.

    Secondary evaluations include assessing complete cell cycle arrest and monitoring any adverse events.

Who can join the trial?

17 criteria

  • Must be a premenopausal woman aged 18 years or older. Premenopausal means still having regular menstrual periods.
  • Must have a type of breast cancer called ER-positive/HER2-negative. This means the cancer cells have certain characteristics related to hormone receptors.
  • The breast cancer must be operable, meaning it can be treated with surgery.
  • Eligible for breast surgery, either breast-conserving surgery or mastectomy. The cancer should be in stage I, II, or operable stage III, but not stage T4.
  • The tumor must be at least 1.0 cm in size.
  • Can have multiple tumors in one or both breasts, but the same tumor area must be checked before and after treatment.
  • Cannot have cancer that has spread to other parts of the body (no distant metastatic disease).
  • The tumor must have at least 1% of cells that are estrogen receptor (ER)-positive.
  • The tumor must be HER2-negative, meaning it does not have high levels of a protein called HER2.
  • The tumor must have a Ki-67 level of 10% or more. Ki-67 is a marker that shows how fast cancer cells are growing.
  • Must have an ECOG Performance Status of 0-1, which means being fully active or having some symptoms but still able to do light work.
  • Must have a resting heart rate of 40 beats per minute or more.
  • Must have normal blood, kidney, and liver function.
  • Must have a negative pregnancy test within 5 weeks before starting the study and again on the first day of treatment.
  • Women who can become pregnant must use highly effective birth control during the study and for 10 days after the last dose.
  • Must sign a Written Informed Consent, agreeing to participate in the study.
  • Must agree to provide tumor and blood samples for further study and review.

Who cannot join the trial?

4 criteria

  • Patients who are not premenopausal. Premenopausal means before menopause, which is the time when a woman's menstrual periods stop permanently.
  • Patients who do not have ER-positive/HER2-negative early breast cancer. ER-positive means the cancer cells grow in response to the hormone estrogen. HER2-negative means the cancer cells do not have high levels of the protein HER2.
  • Patients who are male, as the study is only for female patients.
  • Patients who are not considered part of the vulnerable population selected for this study. Vulnerable population refers to groups of people who may be at a higher risk of harm or exploitation in research.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Giredestrant

    is a medication being studied for its potential to reduce the growth of cancer cells in patients with early breast cancer. It is being tested to see if it can effectively slow down or stop the proliferation of cancer cells in premenopausal women with ER-positive/HER2-negative breast cancer.

  • Triptorelin

    is a therapy used to lower certain hormone levels in the body. In this trial, it is combined with other treatments to see if it enhances their effectiveness in reducing cancer cell growth in premenopausal women with ER-positive/HER2-negative breast cancer.

  • Anastrozole

    is a medication that helps to lower estrogen levels in the body, which can slow or stop the growth of certain types of breast cancer cells. It is being used in combination with triptorelin in this trial to evaluate its effectiveness in treating premenopausal women with ER-positive/HER2-negative breast cancer.

What is already known about the treatment

  • Giredestrant

    Giredestrant is administered orally and is currently being studied in clinical trials for its effectiveness in treating ER-positive/HER2-negative early breast cancer. It is a selective estrogen receptor degrader (SERD) that works by binding to estrogen receptors and promoting their degradation, thereby reducing estrogen-driven cancer cell growth. This medication is classified as a hormonal therapy and is being evaluated for its potential to provide anti-proliferative activity in breast cancer treatment.

  • Triptorelin

    Triptorelin is administered via injection and is used in combination with other medications in clinical trials for ER-positive/HER2-negative early breast cancer. It acts as a gonadotropin-releasing hormone (GnRH) agonist, which reduces the production of estrogen by suppressing ovarian function. This medication is classified as a hormonal therapy and is used to lower estrogen levels, which can help slow the growth of certain types of breast cancer.

  • Anastrozole

    Anastrozole is taken orally and is currently used in clinical trials for treating ER-positive/HER2-negative early breast cancer. It is an aromatase inhibitor that works by blocking the enzyme aromatase, which is involved in estrogen production, thereby reducing estrogen levels in the body. This medication is classified as a hormonal therapy and is used to help prevent the growth of estrogen-dependent breast cancer cells.

Investigated diseases

ER-positive/HER2-negative early breast cancer – This type of breast cancer is characterized by the presence of estrogen receptors (ER-positive) and the absence of human epidermal growth factor receptor 2 (HER2-negative) on the cancer cells. It typically occurs in the early stages of breast cancer development. The cancer cells grow in response to estrogen, which can influence the progression of the disease. This subtype of breast cancer is often considered less aggressive than HER2-positive types. The progression involves the growth and potential spread of cancer cells within the breast tissue and possibly to nearby lymph nodes. Understanding the hormone receptor status is crucial for determining the course of the disease.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2022-503013-32-00Protocol code67-22 PREcoopERAEstimated enrolment220 patientsSponsorETOP IBCSG Partners Foundation

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.